As pain is such a heterogeneous indication, significant opportunities remain for a variety of different and more effective non-opioid treatment options to be developed.

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...

Robot perception and cognition often rely on the integration of information from multiple sensory modalities, such as vision, ...

Additional oral presentations explore odronextamab in areas of high unmet need, including the primary analysis in diffuse large B-cell lymphoma progressing after CAR-T therapy and first results in ...